The results, which validate the safety and a first proof of efficacy for Valedia®, will be presented during a poster session on 11 June from 12 pm to 1 pm (Hall B).
VALBIOTIS INITIAL PUBLIC OFFERING RECORDS HUGE SUCCESSJune 2nd 2017
VALBIOTIS has announced today the huge success of its initial public offering and the admission of its shares for trading on Alternext Paris (ISIN code: FR0013254851 and mnemonic code: ALVAL).
SEBASTIEN PELTIER PRESENTS HIS VISION OF A DIABETES-FREE WORLD AT L’ÉCHAPPÉE VOLÉEApril 24th 2017
Sébastien Peltier has been selected to share his vision of a diabetes-free world at l’Echappée Volée. This is a major event that fosters useful, breakthrough innovation for the common good, in preparation for the next 15 to 20 years.
TWO PARTNERSHIP AGREEMENTS TO ASSESS THE EFFECTS OF TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA®, ON INTESTINAL MICROBIOTAApril 12th 2017
VALBIOTIS, a company that specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients, has announced today the signing of two partnership agreements, one with Biofortis (Merieux NutriSciences), and the other with the Université Catholique de Louvain (Belgium) and Prof. Patrice D. Cani1 (PhD) as part of a program aimed at evaluating the efficacy of TOTUM-63, the active ingredient of Valedia®, on intestinal microbiota.